Navigation Links
Concentra Offers Flu Vaccines to Keep America Working
Date:10/15/2007

ADDISON, Texas, Oct. 15 /PRNewswire/ -- Concentra, the largest occupational health care provider with 320 centers across the nation, has launched a campaign to educate America's workforce about the flu, how it is spread, and how to protect against it. The company expects to vaccinate nearly 300,000 people across the nation, saving businesses more than $200 million in lost productivity.

Concentra Medical Centers offers flu shot to various businesses and communities to keep America's workforce healthy. Working with more than 150,000 of the country's largest employers, as well as 250 employer-based health facilities, Concentra creates health solutions to keep employees well, fit, and safe -- especially during the flu season.

"Concentra is poised to meet the needs of people across the country by providing flu shots when they need them, delivering the right care at the right time," said W. Tom Fogarty, M.D., Concentra's Chief Medical Officer.

Each year 1 in 5 people become sick with influenza. According to the Centers for Disease Control, one flu shot can save a business more than $1,000 in lost time by an employee who is not vaccinated and comes down with the flu. With nearly 300,000 flu vaccines given by Concentra, the company expects to save the nation's economy more than $200 million through flu prevention.

Known as the flu, influenza is an extremely contagious respiratory infection. Flu symptoms are more severe than those of colds, come on more abruptly, and often include high fever, cough, and full body aches. It can cause severe complications, and result in an average of 36,000 deaths each year. To learn about the top 10 myths and facts about the flu and more, log on to: http://www.concentra.com/Flu.

About Concentra(R)

Concentra is a leading health care company that strives to make health care accessible and affordable. The company, through its affiliated providers,
'/>"/>

SOURCE Concentra
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
2. MUSC Research Offers Hope for Those Resistant to Depression Treatment
3. CytoGenix to Present at 2007 International DNA Vaccines Conference in Spain
4. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
5. Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than Vaccines Used in Previous Years
6. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
7. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
8. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
9. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
10. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
(Date:8/21/2014)...  Seventy-one percent of Americans believe the abuse of strong ... health and safety issue in the United States ... by Repass & Partners, a Cincinnati ... severity of the prescription medication abuse problem and the need ... health situation facing our country," Rex Repass , CEO ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... Caremark (NYSE: CVS ) has been named ... by Reputation Institute, in partnership with Forbes Media. The ... RepTrak™ Pulse, a study that measures the 150 largest ... ) Of the companies included in ...
... -- American Oriental Bioengineering, Inc. (NYSE: AOB ) ... (the "NYSE") has notified the Company that it is not ... to timely file its Annual Report on Form 10-K with ... rules, when a Company does not comply with annual report ...
Cached Medicine Technology:CVS Caremark Ranks Among Top 25 Most Reputable Companies in America on Forbes List 2American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
(Date:8/22/2014)... Buying a policy for different life insurance products can ... coverage types by insurers in the U.S. The Quotes Pros ... the public using its sortable tool at http://quotespros.com/life-insurance.html . ... is expected to promote the discounts and special offerings for ... The system is designed to help an adult locate a ...
(Date:8/22/2014)... 22, 2014 The regional economy is ... is on the grow again. The plant ... summer 2016 to boost production of the popular Highlander ... Indiana’s overall investment to $4 billion. This step allows ... providing additional flexibility to adjust its product mix to ...
(Date:8/22/2014)... August 22, 2014 As the ... http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues to grow, ... companies have decided to limit coverage of uterine ... Telegram, Blue Cross-Blue Shield of Massachusetts will no ... involve morcellation as of September 1, 2014. Other ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced ... shorter progression free survival (PFS) in epidermal growth ... chemotherapy treated Asian patients. Also, BIM deletion independently ... , The BIM protein can activate the programmed ... in cells. BIM deletion has been detected in ...
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... developed by Dr. Sen and Dr. Samantha Pearson to ... glasses, contacts, and avoid corrective vision surgery by instead ... Shane Michaels, prompting an investigative review. , “There’s ... billions of dollars in revenue each year—it’s because people ...
Breaking Medicine News(10 mins):Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2
... dubious DEA raids on,legal medical marijuana dispensaries, LOS ANGELES, ... federal government needs to reclassify marijuana. People who,need it should ... The Price Is,Right and Power of 10 host Drew Carey ... on drugs., Voters in 12 states have legalized medical ...
... Minn. -- A Mayo Clinic study of a drug that ... demonstrates that the drug may also be effective in treating ... The study, which was done in mouse models, is featured ... , The National Cancer Institute reports that of 240,510 ...
... pregnant, the probability is much greater that her child ... according to a new Nordic study. The investigation ... in collaboration with international colleagues, and is available online ... comprising more than 12,500 children in Sweden, Finland, and ...
... 1 Dynavax Technologies,Corporation (Nasdaq: DVAX ) announced ... will present an overview of the,company at two investor ... Ostrach will present at the CIBC World Markets 18th ... a.m. ET (5:35,a.m. PT). In addition, Ostrach will present ...
... 1 Amira Pharmaceuticals, Inc. announced,completion of the ... discovered oral drug candidate for the treatment of ... announced the start,of a Phase 1 trial for ... the,same inflammatory response. AM103 and AM803 are ...
... plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the,global specialty biopharmaceutical ... Financial Highlights - Product sales up 41% to $543.1 ... - Net cash provided by operating activities up 51% ... expected to be at least 30% (Q2 guidance: at,least 25%). ...
Cached Medicine News:Health News:Drew Carey Defends Medical Marijuana 2Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 2Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 3Health News:Overweight mothers run greater risk of having hyperactive children 2Health News:Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: